Medical innovation for an aging world: the view from Hong Kong
By 2050 more than 2.1 billion people will be over 60. Hong Kong is confronting this challenge head-on, prioritizing medical innovation for an aging world.
Nancy Ip is the President, The Morningside Professor of Life Science, and the Director of the State Key Laboratory of Molecular Neuroscience at The Hong Kong University of Science and Technology (HKUST). She received her PhD degree in Pharmacology from Harvard University, after which she held the position of Senior Staff Scientist at Regeneron Pharmaceuticals Inc. in New York. Since joining HKUST in 1993, she has served as the Vice-President for Research and Development, the Dean of Science, and the Head of the Department of Biochemistry.
Ip is a world-renowned neuroscientist and internationally recognized for her pioneering research in molecular neuroscience. Her outstanding research has resulted in over 332 scientific papers that have garnered more than 45,200 SCI citations, as well as over 70 patents. She has also been elected to the Chinese Academy of Sciences, the US National Academy of Sciences, the American Academy of Arts and Sciences, the World Academy of Sciences, the Hong Kong Academy of Sciences, and is a recipient of numerous awards and honors including the National Natural Science Awards, the L’OREAL-UNESCO for Women in Science Award, and the 10 Science Stars of China by Nature.
As a distinguished neuroscientist, Ip helps to steer research policy on a global level. She is a member of the Leadership Group of the Davos Alzheimer’s Collaborative. She also actively serves on local committees, such as the Chief Executive’s Council of Advisers, to help steer the strategic development of Hong Kong. As the Council Chair and founding member of the Greater Bay Area Association of Academicians, Ip plays a pivotal role in fostering cooperation among academics in Hong Kong and the Mainland, towards contributing to the advancement of science and technology in the Greater Bay Area.
By 2050 more than 2.1 billion people will be over 60. Hong Kong is confronting this challenge head-on, prioritizing medical innovation for an aging world.
China is projected to have 22.5 million cases of Alzheimer's by 2050.